<p>Veracyte, Inc.（納斯達克代碼：VCYT - 獲取免費報告）在週五的午盤交易中，股價下跌了 4.5%，原因是內部人士出售了該公司的股票。該公司股價最低曾達到 45.81 美元，最後交易價格為 45.2750 美元。在交易中，共成交 61,820 股，較平均交易量 1,098,376 股下降了 94%。該股票此前收盤價為 47.41 美元。</p>
<p>具體來説，內部人士 John Leite 在 12 月 4 日（星期四）出售了 1,278 股公司的股票，交易價格為每股平均 47.51 美元，總交易額為 60,717.78 美元。交易後，該內部人士持有 82,113 股公司股票，價值為 3,901,188.63 美元。這次交易使其持股比例減少了 1.53%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，首席執行官 Marc Stapley 在 12 月 4 日（星期四）出售了 7,668 股公司的股票，交易價格為每股平均 47.09 美元，總交易額為 361,086.12 美元。交易完成後，首席執行官持有 318,603 股公司股票，價值約為 15,003,015.27 美元。這代表其持股比例減少了 2.35%。該出售的披露信息可在 SEC 備案中找到。在其他消息中，首席財務官 Rebecca Chambers 在 12 月 4 日（星期四）出售了 13,278 股股票，交易價格為每股平均 46.84 美元，總交易額為 621,941.52 美元。出售後，首席財務官持有 109,496 股公司股票，價值為 5,128,792.64 美元。這代表其持股比例減少了 10.81%。該交易在 SEC 備案中披露，相關信息可通過 SEC 網站獲取。</p>
<h2>分析師評級升級與降級</h2>
<p>幾家研究公司最近對 VCYT 進行了評估。Weiss Ratings 在週一的研究報告中重申了對 Veracyte 股票的 “持有（c）” 評級。Guggenheim 在 11 月 5 日的報告中將 Veracyte 的目標價格從 40.00 美元上調至 45.00 美元，並給予該公司 “買入” 評級。Needham &amp; Company LLC 在 11 月 5 日的研究報告中將 Veracyte 的目標價格從 41.00 美元上調至 44.00 美元，並給予該股票 “買入” 評級。摩根士丹利在週一的研究報告中將 Veracyte 的目標價格從 40.00 美元上調至 48.00 美元，並給予該公司 “減持” 評級。最後，瑞銀集團在 11 月 5 日的研究報告中將 Veracyte 的目標價格從 42.00 美元上調至 48.00 美元，並給予該公司 “買入” 評級。一位股票研究分析師對該股票給予了強烈買入評級，五位給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價格為 45.43 美元。</p>
<p><strong>查看我們對 Veracyte 的最新分析</strong></p>
<h2>Veracyte 股票表現</h2>
<p>該股票的 50 日移動平均線為 39.11 美元，200 日移動平均線為 31.88 美元。該公司的市值為 35.8 億美元，市盈率為 119.45，貝塔值為 1.83。</p>
<p>Veracyte（納斯達克代碼：VCYT - 獲取免費報告）最近一次發佈財報是在 11 月 4 日（星期二）。該生物技術公司報告本季度每股收益為 0.51 美元，超出市場共識預期的 0.32 美元，超出幅度為 0.19 美元。該公司本季度的收入為 1.3187 億美元，而市場共識預期為 1.2462 億美元。Veracyte 的股本回報率為 7.23%，淨利潤率為 6.12%。該公司本季度的收入較去年同期增長了 13.8%。去年同期，該公司每股收益為 0.33 美元。整體來看，股票分析師預計 Veracyte, Inc.在當前財年將發佈 0.68 美元的每股收益。</p>
<h2>對 Veracyte 的對沖基金看法</h2>
<p>對沖基金最近增加或減少了對該股票的持倉。BNP PARIBAS ASSET MANAGEMENT Holding S.A.在第二季度購買了 Veracyte 的新頭寸，價值約為 25,000 美元。First Horizon Corp 在第三季度購買了 Veracyte 的新頭寸，價值約為 31,000 美元。Osaic Holdings Inc.在第二季度將其在 Veracyte 的持股增加了 289.9%。Osaic Holdings Inc.現在持有 1,201 股該生物技術公司的股票，價值 33,000 美元，此前在上個季度又購買了 893 股。Headlands Technologies LLC 在第一季度購買了 Veracyte 的新頭寸，價值 48,000 美元。最後，Neo Ivy Capital Management 在第三季度購買了 Veracyte 的新頭寸，價值 56,000 美元。</p>
<h2>Veracyte 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Veracyte, Inc.從事診斷產品的研究、開發和商業化。該公司的產品組合包括 Afirma、Percepta 和 Envisia。其目標是治療甲狀腺癌、改善肺癌篩查以及明確特發性肺纖維化的診斷。該公司由 Bonnie H.創立。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Veracyte</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>Salesforce 股票如彈簧般蓄勢待發，準備反彈</li>
<li>道瓊斯工業平均指數（DJIA）是什麼？</li>
<li>Marvell 的反彈延續：數據中心和 AMZN 芯片推動股價上漲</li>
<li>如何一步一步購買便宜股票</li>
<li>Ross Stores 股票能否在聖誕節前達到 200 美元？分析師認為有三個理由支持這一觀點</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Veracyte 嗎？</h2>
<p>在考慮 Veracyte 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Veracyte 並不在名單上。</p>
<p>雖然 Veracyte 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

VCYT

<p>Veracyte 的股票在關鍵高管，包括首席執行官 Marc Stapley 和首席財務官 Rebecca Chambers 的內部出售後下跌了 4.5%。該股票交易最低價為 45.81 美元，交易量顯著下降。分析師對該股票的評級不一，普遍持中性買入意見，平均目標價為 45.43 美元。最近的財報超出預期，收入同比增長了 13.8%</p>

<p>Veracyte, Inc. (NASDAQ:VCYT - Get Free Report)'s stock price fell 4.5% during mid-day trading on Friday after an insider sold shares in the company. The company traded as low as $45.81 and last traded at $45.2750. 61,820 shares traded hands during trading, a decline of 94% from the average session volume of 1,098,376 shares. The stock had previously closed at $47.41.</p>
<div class="lb-trans"><p>Veracyte, Inc.（納斯達克代碼：VCYT - 獲取免費報告）在週五的午盤交易中，股價下跌了 4.5%，原因是內部人士出售了該公司的股票。該公司股價最低曾達到 45.81 美元，最後交易價格為 45.2750 美元。在交易中，共成交 61,820 股，較平均交易量 1,098,376 股下降了 94%。該股票此前收盤價為 47.41 美元。</p>
</div><p>Specifically, insider John Leite sold 1,278 shares of the business's stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $47.51, for a total transaction of $60,717.78. Following the transaction, the insider owned 82,113 shares in the company, valued at $3,901,188.63. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, CEO Marc Stapley sold 7,668 shares of the company's stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $47.09, for a total transaction of $361,086.12. Following the completion of the transaction, the chief executive officer owned 318,603 shares in the company, valued at approximately $15,003,015.27. This represents a 2.35% decrease in their position. The disclosure for this sale is available in the SEC filing. In other news, CFO Rebecca Chambers sold 13,278 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $46.84, for a total transaction of $621,941.52. Following the sale, the chief financial officer owned 109,496 shares in the company, valued at $5,128,792.64. This represents a 10.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>具體來説，內部人士 John Leite 在 12 月 4 日（星期四）出售了 1,278 股公司的股票，交易價格為每股平均 47.51 美元，總交易額為 60,717.78 美元。交易後，該內部人士持有 82,113 股公司股票，價值為 3,901,188.63 美元。這次交易使其持股比例減少了 1.53%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，首席執行官 Marc Stapley 在 12 月 4 日（星期四）出售了 7,668 股公司的股票，交易價格為每股平均 47.09 美元，總交易額為 361,086.12 美元。交易完成後，首席執行官持有 318,603 股公司股票，價值約為 15,003,015.27 美元。這代表其持股比例減少了 2.35%。該出售的披露信息可在 SEC 備案中找到。在其他消息中，首席財務官 Rebecca Chambers 在 12 月 4 日（星期四）出售了 13,278 股股票，交易價格為每股平均 46.84 美元，總交易額為 621,941.52 美元。出售後，首席財務官持有 109,496 股公司股票，價值為 5,128,792.64 美元。這代表其持股比例減少了 10.81%。該交易在 SEC 備案中披露，相關信息可通過 SEC 網站獲取。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級升級與降級</h2>
</div><p>Several research firms have recently weighed in on VCYT. Weiss Ratings restated a &#34;hold (c)&#34; rating on shares of Veracyte in a research note on Monday. Guggenheim increased their price objective on shares of Veracyte from $40.00 to $45.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, November 5th. Needham &amp; Company LLC boosted their target price on Veracyte from $41.00 to $44.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, November 5th. Morgan Stanley increased their price objective on shares of Veracyte from $40.00 to $48.00 and gave the company an &#34;underweight&#34; rating in a research report on Monday. Finally, UBS Group boosted their target price on Veracyte from $42.00 to $48.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $45.43.</p>
<div class="lb-trans"><p>幾家研究公司最近對 VCYT 進行了評估。Weiss Ratings 在週一的研究報告中重申了對 Veracyte 股票的 “持有（c）” 評級。Guggenheim 在 11 月 5 日的報告中將 Veracyte 的目標價格從 40.00 美元上調至 45.00 美元，並給予該公司 “買入” 評級。Needham &amp; Company LLC 在 11 月 5 日的研究報告中將 Veracyte 的目標價格從 41.00 美元上調至 44.00 美元，並給予該股票 “買入” 評級。摩根士丹利在週一的研究報告中將 Veracyte 的目標價格從 40.00 美元上調至 48.00 美元，並給予該公司 “減持” 評級。最後，瑞銀集團在 11 月 5 日的研究報告中將 Veracyte 的目標價格從 42.00 美元上調至 48.00 美元，並給予該公司 “買入” 評級。一位股票研究分析師對該股票給予了強烈買入評級，五位給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價格為 45.43 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Veracyte</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Veracyte 的最新分析</strong></p>
</div><h2>Veracyte Stock Performance</h2>
<div class="lb-trans"><h2>Veracyte 股票表現</h2>
</div><p>The stock has a fifty day moving average of $39.11 and a 200-day moving average of $31.88. The company has a market cap of $3.58 billion, a PE ratio of 119.45 and a beta of 1.83.</p>
<div class="lb-trans"><p>該股票的 50 日移動平均線為 39.11 美元，200 日移動平均線為 31.88 美元。該公司的市值為 35.8 億美元，市盈率為 119.45，貝塔值為 1.83。</p>
</div><p>Veracyte (NASDAQ:VCYT - Get Free Report) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.19. The business had revenue of $131.87 million during the quarter, compared to the consensus estimate of $124.62 million. Veracyte had a return on equity of 7.23% and a net margin of 6.12%.The business's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the company earned $0.33 earnings per share. As a group, equities analysts anticipate that Veracyte, Inc. will post 0.68 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Veracyte（納斯達克代碼：VCYT - 獲取免費報告）最近一次發佈財報是在 11 月 4 日（星期二）。該生物技術公司報告本季度每股收益為 0.51 美元，超出市場共識預期的 0.32 美元，超出幅度為 0.19 美元。該公司本季度的收入為 1.3187 億美元，而市場共識預期為 1.2462 億美元。Veracyte 的股本回報率為 7.23%，淨利潤率為 6.12%。該公司本季度的收入較去年同期增長了 13.8%。去年同期，該公司每股收益為 0.33 美元。整體來看，股票分析師預計 Veracyte, Inc.在當前財年將發佈 0.68 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Veracyte</h2>
<div class="lb-trans"><h2>對 Veracyte 的對沖基金看法</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Veracyte during the second quarter worth approximately $25,000. First Horizon Corp bought a new position in Veracyte in the third quarter worth approximately $31,000. Osaic Holdings Inc. grew its stake in Veracyte by 289.9% in the second quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 893 shares in the last quarter. Headlands Technologies LLC purchased a new position in Veracyte during the 1st quarter worth $48,000. Finally, Neo Ivy Capital Management bought a new stake in Veracyte during the 3rd quarter valued at $56,000.</p>
<div class="lb-trans"><p>對沖基金最近增加或減少了對該股票的持倉。BNP PARIBAS ASSET MANAGEMENT Holding S.A.在第二季度購買了 Veracyte 的新頭寸，價值約為 25,000 美元。First Horizon Corp 在第三季度購買了 Veracyte 的新頭寸，價值約為 31,000 美元。Osaic Holdings Inc.在第二季度將其在 Veracyte 的持股增加了 289.9%。Osaic Holdings Inc.現在持有 1,201 股該生物技術公司的股票，價值 33,000 美元，此前在上個季度又購買了 893 股。Headlands Technologies LLC 在第一季度購買了 Veracyte 的新頭寸，價值 48,000 美元。最後，Neo Ivy Capital Management 在第三季度購買了 Veracyte 的新頭寸，價值 56,000 美元。</p>
</div><h2>Veracyte Company Profile</h2>
<div class="lb-trans"><h2>Veracyte 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.</p>
<div class="lb-trans"><p>Veracyte, Inc.從事診斷產品的研究、開發和商業化。該公司的產品組合包括 Afirma、Percepta 和 Envisia。其目標是治療甲狀腺癌、改善肺癌篩查以及明確特發性肺纖維化的診斷。該公司由 Bonnie H.創立。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Veracyte</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>Marvell's Rally Extends: Data Centers and AMZN Chips Boost Shares</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>Could Ross Stores Stock Hit $200 by Christmas? Here Are 3 Reasons Analysts Think So</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Veracyte</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>Salesforce 股票如彈簧般蓄勢待發，準備反彈</li>
<li>道瓊斯工業平均指數（DJIA）是什麼？</li>
<li>Marvell 的反彈延續：數據中心和 AMZN 芯片推動股價上漲</li>
<li>如何一步一步購買便宜股票</li>
<li>Ross Stores 股票能否在聖誕節前達到 200 美元？分析師認為有三個理由支持這一觀點</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Veracyte Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Veracyte 嗎？</h2>
</div><p>Before you consider Veracyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Veracyte 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Veracyte 並不在名單上。</p>
</div><p>While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Veracyte 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Veracyte（NASDAQ:VCYT）股價因內部人士出售股票下跌 4.5%